1. Home
  2. CCCC vs SKYE Comparison

CCCC vs SKYE Comparison

Compare CCCC & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCCC
  • SKYE
  • Stock Information
  • Founded
  • CCCC 2015
  • SKYE 2012
  • Country
  • CCCC United States
  • SKYE United States
  • Employees
  • CCCC N/A
  • SKYE N/A
  • Industry
  • CCCC Biotechnology: Pharmaceutical Preparations
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCCC Health Care
  • SKYE Health Care
  • Exchange
  • CCCC Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • CCCC 304.8M
  • SKYE 176.8M
  • IPO Year
  • CCCC 2020
  • SKYE N/A
  • Fundamental
  • Price
  • CCCC $6.03
  • SKYE $5.89
  • Analyst Decision
  • CCCC Buy
  • SKYE Strong Buy
  • Analyst Count
  • CCCC 7
  • SKYE 4
  • Target Price
  • CCCC $8.71
  • SKYE $19.25
  • AVG Volume (30 Days)
  • CCCC 2.6M
  • SKYE 386.3K
  • Earning Date
  • CCCC 08-06-2024
  • SKYE 01-01-0001
  • Dividend Yield
  • CCCC N/A
  • SKYE N/A
  • EPS Growth
  • CCCC N/A
  • SKYE N/A
  • EPS
  • CCCC N/A
  • SKYE N/A
  • Revenue
  • CCCC $20,036,000.00
  • SKYE N/A
  • Revenue This Year
  • CCCC $26.24
  • SKYE N/A
  • Revenue Next Year
  • CCCC N/A
  • SKYE N/A
  • P/E Ratio
  • CCCC N/A
  • SKYE N/A
  • Revenue Growth
  • CCCC N/A
  • SKYE N/A
  • 52 Week Low
  • CCCC $1.06
  • SKYE $1.44
  • 52 Week High
  • CCCC $11.88
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • CCCC 57.54
  • SKYE 34.36
  • Support Level
  • CCCC $4.36
  • SKYE $5.95
  • Resistance Level
  • CCCC $7.66
  • SKYE $6.83
  • Average True Range (ATR)
  • CCCC 0.56
  • SKYE 0.82
  • MACD
  • CCCC 0.21
  • SKYE 0.09
  • Stochastic Oscillator
  • CCCC 50.68
  • SKYE 21.26

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: